Ligelizumab
Ligelizumab (INN; development code QGE031) is a humanized monoclonal antibody designed for the treatment of severe asthma and chronic spontaneous urticaria.[1] It binds to IGHE an acts as an immunomodulator.[2]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | IGHE |
| Clinical data | |
| Other names | QGE031 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6534H10000N1716O2038S44 |
| Molar mass | 146612.49 g·mol−1 |
This drug was developed by Novartis Pharma AG. Research funded by Novartis Pharma (ClinicalTrials.gov number, NCT02477332) concluded that Ligelizumab was more effective in treating chronic spontaneous urticaria than omalizumab or placebo [3].
Adverse drug effects
gollark: To obfuscate the trail obviously.
gollark: You have a good idea about the others?!
gollark: No, apiomemetics, not applied apiology.
gollark: Wait, actually, 11 isn't a bad candidate for baidicootness.
gollark: I kind of suspect 2.
References
- Statement On A Nonproprietary Name Adopted By The USAN Council - Ligelizumab, American Medical Association.
- World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
- Maurer, Marcus; Giménez-Arnau, Ana M.; Sussman, Gordon; Metz, Martin; Baker, Diane R.; Bauer, Andrea; Bernstein, Jonathan A.; Brehler, Randolf; Chu, Chia-Yu; Chung, Wen-Hung; Danilycheva, Inna (2019-10-02). "Ligelizumab for Chronic Spontaneous Urticaria". New England Journal of Medicine. doi:10.1056/NEJMoa1900408.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.